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Background: Little is known about the clinical features and treatment of Chinese patients with Parkinson disease
(PD).
Methods: A large cross-sectional survey of clinical features, medication use, and motor complications was
conducted in 901 consecutive PD patients, from 42 randomly selected university-affiliated hospitals in four urban
economic regions of China, between December 2006 and May 2007.
Results: The 901 PD patients had age range 30 to 88, and median disease duration 50 months. Most (737, 81.8%)
used L-dopa (median 375 mg/day), and often added low doses of other antiparkinsonian agents. Among
L-dopa-treated patients, the prevalence of motor complications was low (dyskinesias: 8.5%; motor fluctuations:
18.6%), even among patients with disease duration ≥11 years (dyskinesias: 18.1%; motor fluctuations: 42.2%). Higher
L-dopa use was associated with higher occurrence of dyskinesias (OR 2.44; 95% CI 1.20-5.13) and motor fluctuations
(OR 2.48; 95% CI 1.49-4.14). Initiating PD treatment with L-dopa alone (OR 0.46; 95% CI 0.22-0.95) or in combination
with other medications (OR 0.41; 95% CI 0.19-0.87) was associated with less dyskinesia than treatment initiated with
non-L-dopa medication.
Conclusions: Many Chinese PD patients are treated with low-dose L-dopa and added low-dose antiparkinsonian
agents, with a low prevalence of motor complications, which might be influenced by Chinese culture.
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Parkinson disease (PD) was described in China more
than 2400 years ago under the name “wind shaking syn-
drome,” and traditional medications such as the “Jinya
wine” and the “tremor pill” were recommended as early
as the Tang (581-682 AD) and Ming (1549-1613 AD)
dynasties [1]. Chinese culture covers not only material
as medications, but also intangible, i.e. traditional ideas,
values, and code of conduct. Culture affects generation* Correspondence: wuzhangzhenxin@medmail.com.cn
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Traditional features of Chinese culture permeate the
care of the elderly afflicted by chronic neurodegenerative
diseases. However, most clinical studies on PD treatment
have been conducted in Western countries [2-4]. We
therefore conducted a large nationwide survey to
characterize the clinical features and treatment of PD
patients in China and to compare our results with data
from Western countries. Patients were recruited from
randomly selected hospitals in seven provincial capital
cities representing four economic regions of China with
an estimated population of 73.2 million.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Design and sampling procedure
In China, as in the West, most neurology and movement
disorder clinics are located in university- affiliated hospi-
tals in large cities. Most patients are either already diag-
nosed or are referred for diagnostic confirmation. We
therefore decided to recruit patients from university-
affiliated hospitals in provincial capitals. This also ensured
the quality of PD diagnosis and clinical data collection.
We selected seven provincial capitals from four regions in
China with various levels of economic and health care de-
velopment (average 2010 GDP/capita in Chinese Yuan/
medical personnel per 1000 persons in 2009): the Gulf of
Bohai (Beijing: 70,234/12.9), Changjiang Delta (Shanghai
and Hangzhou: 53,573/9.5 and 5.7), Pearl-River Delta
(Guangzhou: 39,978/ 5.0), and Mid-West area (Xian,
Wuhan and Jinan: 29,997/4.5, 4.0 and 4.4) [5].
In these regions, there are a total of 349 university-
affiliated teaching hospitals and 42 were randomly
selected for the study. The number of participants in
each city was estimated a priori, in proportion to its
population size. The study team included seven field su-
pervisors, one in each city, and 135 physicians (64 senior
neurologists, 46 junior neurologists, and 25 graduate stu-
dents). PD was diagnosed according to the UK Queen
Square Brain Bank diagnostic clinical criteria. Between
December 2006 and May 2007, we consecutively re-
cruited 907 individuals with either diagnosed (n = 844) or
suspected PD (n = 63). The principal investigator (ZZX)
reviewed all medical records. Doubtful diagnoses were
followed up to one year with additional neurological ex-
aminations, and further assessment of the long-term re-
sponse to L-dopa/DCI, smell test, or brain imaging when
necessary. Finally, 901 PD patients were eligible and 6
were excluded due to a final diagnosis of atypical Parkin-
sonism. All eligible patients agreed to participate and
gave written consent. Initial diagnosis and follow-up care
was performed at the same participating hospitals in 507
(56.3%) patients. The other 209 patients were referred
from community or district hospitals, with an incorrect
initial diagnosis in 66.5% (139/209). The Ethics Commit-
tee on Human Research at the Peking Union Medical
College Hospital approved the study.
Data collection
Clinical data for 901 consecutive PD patients were col-
lected by 142 interviewers in the 42 participating out-
patient clinics following a standard protocol. Data
collection included basic demographics, family and
medical history, past and current treatment, and co-
morbidities. We also evaluated motor symptoms and
signs using standardized instruments such as Hoehn
and Yahr Stage (HYS), the Unified Parkinson’s Disease
Rating Scale I-IV (UPDRS), Mini-Mental State Examination(MMSE), Hamilton Depression Scale, and pertinent labora-
tory tests. All interviewers received a two-day training
resulting with videotaped interviews in an inter-rater reli-
ability for UPDRS and HYS of more than 0.90.
Data analyses
All statistical analyses were performed using SAS (version
8.0) with two-sided alpha of 0.05. In descriptive analyses,
we used mean and standard deviation (SD) for normally
distributed continuous variables, median and interquartile
range (IQ) for continuous variables with skewed distri-
bution, and proportions for categorical variables. We
compared demographic and clinical features by disease
duration and economic regions. Cardinal variables were
compared with the Kruskal-Wallis test, dichotomous
variables with 2 × 4 Chi-square test. We used multivari-
ate logistic regression to test the relationship between
motor complications and demographic and clinical
features. Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were reported accordingly.
Results
Clinical features and medication uses
Table 1 shows the demographic and clinical characteris-
tics of 901 Chinese PD patients overall by economic re-
gions. Median age at onset was 61 years. The majority of
study participants (80.8%) were at HYS-2 or higher, and
median disease duration was 50 months for all patients
and 70 months for patients with HYS ≥2.5.
At enrollment, L-dopa/DCI was the most commonly
used antiparkinsonian drug (737, 81.8%), followed by
dopamine agonists (296, 32.9%) and amantadine (222,
24.6%) (Table 2). Among L-dopa/DCI users, 596 (80.9%)
initiated treatment with L-dopa/DCI and at the time of
the survey, 498 patients (67.6%) combined L-dopa/DCI
with other antiparkinsonian drugs: dopamine agonists
(269, 36.5%), amantadine (169, 22.9%), anticholinergics
(126, 17.1%), or selegiline (75, 10.2%) (Figure 1); includ-
ing former users of L-dopa/DCI plus these drugs, the
percentages increased to 46.1%, 41.5%, 39.6%, and 17.2%
respectively. Notably, all these drugs were taken at doses
lower than those at which they were licensed or recom-
mended for use in published trials from Europe and
North America [6]. In our patients, the daily median
dose was 375 mg for L-dopa, 200 mg for amantadine,
and 5 mg for selegiline, consistently across all regions
(Table 2). For dopamine agonists, the median daily doses
were 75 mg for piribedil, 0.38 mg for pergolide, 3.75 mg
for bromocriptine, and 0.5 mg for pramipexole. At the
time of our survey, 32.4% of the 737 L-dopa/DCI users
were receiving single-drug therapy, while 46.1% were
taking two drugs, 17.8% three drugs, and 3.7% four or
five drugs. The median (IQ) dosage of calculated L-
dopa/DCI equivalent daily dose (LED) [7] was 450 (350)












Men, n (%) 562 (62.4) 180 (63.6) 174 (63.3) 67 (60.9) 141 (60.5) 0.87
Age at survey (yr) 67.0 (15.0) 68.0 (15.0) 66.0 (15.0) 67.5 (13.0) 67.0 (15.0) 0.43
<60, n (%) 254 (28.2) 76 (26.9) 87 (31.6) 27 (24.5) 97 (41.6)
60-69, n (%) 266 (29.5) 81 (28.6) 111 (40.4) 36 (32.7) 72 (30.9)
≥70, n (%) 381 (42.3) 126 (44.5) 77 (28.0) 47 (42.7) 64 (27.5)
Education (yr) 10.7 (4.6) 12.2 (4.2) 10.3 (4.5) 9.4 (5.1) 10.0 (4.3) <0.001
Occupation, n (%) <0.001
Labor/ Service, n (%) 392 (43.5) 89 (31.5) 146 (53.1) 58 (52.7) 99 (42.5)
Administrative, n (%) 253 (28.1) 107 (37.8) 51 (18.5) 24 (21.8) 71 (30.5)
Professional, n (%) 256 (28.4) 87 (30.7) 78 (28.4) 28 (25.5) 63 (27.0)
Living on personal income, n (%) 722 (80.1) 261 (92.2) 212 (77.1) 69 (62.7) 180 (77.3) <0.001
Age of 1st symptom onset (yr) 61.0 (15.0) 60.0 (15.0) 60.0 (16.0) 61.5 (18.0) 63 · 0 (14.0) 0.35
Age at diagnosis (yr) 62.8 (15.6) 61.9 (16.0) 61.7 (15.6) 63.1 (17.8) 63.8 (13.5) 0.29
Months from onset to 1st visit 3.0 (12.0) 4.0 (12.0) 3.0 (9.0) 3.0 (12.0) 3.0 (12.0) 0.11
Tremor as 1st symptom, n (%) 586 (65.4) 185 (65.4) 170 (61.8) 75 (68.2) 156 (67.0) 0.55
Resting tremor, n (%) 758 (84.1) 241 (85.2) 233 (84.7) 88 (80.0) 143 (84.1) 0.64
Rigidity, n (%) 832 (92.3) 270 (95.4) 253 (92.0) 102 (92.7) 207 (88.8) 0.05
Bradykinesia, n (%) 881 (97.8) 281 (99.3) 269 (97.8) 108 (98.2) 223 (95.7) 0.05
Hoehn-Yahr stage, n (%) <0.001
1.0-1.5 173 (19.2) 44 (15.6) 71 (18.9) 14 (12.7) 44 (18.9)
2.0-2.5 560 (62.2) 189 (66.8) 151 (58.4) 84 (76.4) 136 (58.4)
3.0 114 (12.6) 34 (12.0) 45 (12.9) 5 (4.6) 30 (12.9)
4.0-5.0 54 (6.0) 16 (5.7) 8 (9.9) 7 (6.4) 23 (9.9)
UPDRS-II, scores 11.0 (8.0) 10.0 (8.0) 10.0 (11.0) 11.0 (7.0) 12.0 (11.0) <0.001
UPDRS-III, scores 25.0 (20.0) 27.0 (20.0) 23.0 (18.0) 24.0 (19.0) 26.0 (23.0) 0.02
PD duration, months 50.0 (58.0) 56.0 (61.0) 50.0 (56.0) 49.0 (56.0) 44.0 (53.0) <0.001
Hoehn-Yahr stage 1.0-2.0 37.0 (43.0) 41.0 (48.0) 40.0 (38.0) 37.0 (48.0) 27.0 (45.0)
Hoehn-Yahr stage 2.5-5 70.0 (70.0) 82.0 (78.5) 72.0 (69.0) 76.0 (75.5) 56.0 (53.5)
MMSE score < cutoff, n (%) 225 (25.0) 55 (19.4) 61 (22.2) 30 (27.3) 79 (33.9) 0.005
Depressive symptom, n (%) 406 (45.1) 100 (35.3) 113 (41.1) 60 (54.5) 133 (57.1) 0.004
Abbreviations: IQ, interquartile range; Values are given as Median (IQ) unless stated otherwise; MMSE cutoff score for aged 55 and over: ≤19 for illiterate, ≤22 for
1-6 years of education, ≤ 26 for ≥7 years of education. Depressive symptom: Hamilton Depression Scale (17 items) ≥9. Cardinal variables were compared with the
Kruskal-Wallis test, dichotomous variables with 2x4 –Chi-square test.
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with disease duration. Chinese herbs were used only in
25 mild patients (UPDRS III = 19.1), in 12 as single-drug
therapy and in13 as supplementary therapy.
The four economic regions differed in demographic
and PD-related characteristics (Table 1). Compared to
patients from other regions, those from Gulf of Bohai
were more likely to be professionals or administrators
with a higher education level and financial independ-
ence. However, they did not differ in age of onset or
diagnosis, or main PD symptoms or signs. Mid-West
was the least developed region. Compared to this region,
PD patients from the Gulf of Bohai had longer diseaseduration and yet better HYS and activities of daily living
(UPDRS-II) scores. This regional difference of disease
duration was evident even in stratified analyses by HYS
subgroups. The use of amantadine and selegiline was
also related to economic development (Table 2).
Disease progression and motor complications
Of the 737 L-dopa/DCI users, 137 (18.6%) had motor
fluctuations and 63 (8.6%) had dyskinesias. The preva-
lence of motor complications increased with disease dur-
ation (Figure 1): the prevalence of dyskinesia was 3.4%
among patients with 3 years of disease, 6.2% among pa-
tients with 4-6 years of disease as compared to 18.1%
Table 2 Medication use of 901 PD patients
Medication use
Total Gulf of Bohai Changjian Delta Pearl-River Delta Mid-westArea P
Value(n = 901) (n = 283) (n = 275) (n = 110) (n = 233)
LED a 450 (350) 500 (330) 435 (360) 525 (353) 375 (330) 0.01
LD/DCI treatment, n (%) 737 (81.8) 227 (80.2) 231 (84.0) 100 (90.9) 179 (76.8) 0.01
LD Dose, mg/d 375 (265) 375 (200) 375 (300) 375 (300) 375 (250) 0.81
LD/DCI Duration, months b 29.5 (51.0) 36.0 (54.0) 34.0 (51.0) 21.0 (45.0) 16.0 (38.0) <0.001
Dopamine agonists, n (%) 296 (32.7) 98 (34.6) 83 (30.2) 53 (48.2) 62 (26.6) <0.001
Duration, months b 12.0 (28.0) 18.0 (32.0) 9.5 (23.0) 12.0 (21.0) 8.0 (19.5) 0.004
Amantadine, n (%) 222 (24.6) 88 (31.0) 77 (28.0) 25 (22.7) 32 (13.7) <0.001
Dose, mg/d 200 (0) 200 (0) 200 (100) 200 (0) 200 (100) 0.07
Duration, months b 21.0 (43.0) 29.5 (62.5) 11.0 (34.0) 10.5 (21.5) 18.5 (53.5) 0.002
Anticholinergics, n (%) 169 (18.8) 43 (15.2) 64 (23.3) 15 (13.6) 47 (20.2) 0.04
Dose, mg/d 4.0 (2.0) 4.0 (3.0) 3.0 (2.0) 4.0 (4.0) 4.0 (4.0) 0.02
Duration, months b 23.0 (51.0) 38.0 (62.0) 25.0 (57.0) 17.0 (21.0) 20.2 (41.0) 0.23
Entacapone, n (%) 55 (6.1) 17 (6.0) 8 (2.9) 11 (10.0) 19 (8.2) 0.02
Dose, mg/d 300 (200) 300 (200) 250 (200) 300 (200) 300 (100) 0.68
Duration, months b 5.5 (14.0) 9.0 (14.0) 9.0 (20.0) 4.0 (5.0) 1.5 (6.5) 0.04
Selegiline, n (%) 87 (9.7) 36 (12.7) 36 (13.1) 13 (11.8) 2 (0.9) <0.001
Dose, mg/d 5.0 (2.5) 5.0 (2.5) 5.0 (5.0) 5.0 (0.0) 5.0 (0.0) 0.63
Duration, months b 15.0 (27.0) 24.0 (23.0) 12.0 (33.0) 7.5 (22.0) 15.0 (0.0) 0.87
All LD/DCI users (n=737)
Motor fluctuation, n (%) 137 (18.6) 47 (20.7) 50 (21.6) 11 (11.0) 29 (16.2) 0.09
Dyskinesias, n (%) 63 (8.6) 22 (9.7) 15 (6.5) 11 (11.0) 15 (8.4) 0.49
Abbreviations: LED: L-dopa/DCI equivalent daily dose; LD: L-dopa; IQ: Interquartile range.
Values are given as Median (IQ) unless stated otherwise;
a n = 806.
b Data are available for duration of medication user: n = 726 for L-dopa, n = 267 for dopaming agonists, n = 211 for amantadine, n = 159 for anticholinergics, n = 46
for entacapone, and n = 65 for selegiline.
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the corresponding numbers for motor fluctuations were
2.9%, 14.9%, and 42.2%, respectively. Among young-onset
patients (<50 years, n = 111), median disease duration
was 6.4 years, HYS 2, and the prevalence of dyskinesias
and motor fluctuations 12.6% and 22.5%, respectively. Of
the 137 patients with motor fluctuations, 38 had dyskine-
sias. As a proxy for the severity of motor fluctuations, the
median score of UPDRS item 39 (off hours in total wak-
ing time) was 1 for both groups of patients.
Although the overall dosages of L-dopa/DCI and total
LED were low, they increased with disease duration, from
350 mg/day or 375 mg/day for patients with <3 years of the
disease to 500 mg/day or 670 mg/day for those with
≥11 years. The dosage of other antiparkinsonian medica-
tions remained steadily low throughout the course of the
disease, but the proportion of adjuvant medication use in-
creased with disease duration (Figure 1). At enrollment, the
proportion of adjuvant therapy in addition to L-dopa/DCI
among patients with <3 years of the disease was 24.4% fordopamine agonists, 17.6% for amantadine, 3.9% for selegi-
line, and 10.2% for anticholinergics. In contrast, the propor-
tions among patients with ≥11 years of disease duration
was 49.4% for dopamine agonists, 28.9% for amantadine,
16 · 9% for selegiline, and 22.9% for anticholinergics.
In multivariate analyses, HYS ≥3 and L-dopa doses
≥400 mg/d were associated with higher occurrence of
dyskinesia (Table 3), whereas initiation of L-dopa/DCI
alone or added to other medication was associated with
lower occurrence of dyskinesia. PD duration ≥5 years,
HYS ≥3, and L-dopa doses ≥600 mg/d were each associ-
ated with higher occurrence of motor fluctuations. On
the other hand, initiation of treatment with L-dopa/DCI
and delayed initiation of treatment one year after onset
were not associated with higher occurrence of motor
fluctuations.
Discussion
To the best of our knowledge, this is to date the largest
hospital-based clinical survey of PD patients in China.
Figure 1 Prevalence of Motor Complications and Medication uses by PD Duration among L-dopa/DCI Users. Abbreviations: Anticholin,
Anticholinergics; IQ, Interquartile range; DA, dopamine agonists; UPDRS, Unified Parkinson’s Disease Rating Scale; Values are given as median (IQ)
unless stated otherwise.
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tative of urban regions in China since sample size was es-
timated a priori in proportion to regional population size;
nearly all patients with neurological symptoms are man-
aged primarily by university outpatient clinics or will be
referred to them for final diagnosis and treatment. We
may have missed patients with very advanced PD while
those with early disease may have been somewhat over-
represented as a consequence of the improvements in the
Chinese health assurance and social security system.
Comparisons with Western countries therefore need to
be made within classes of illness duration. Like their
counterparts in Western countries, PD patients in China
are predominantly men with average symptom onset in
the early sixties; bradykinesia and rigidity are the main
signs and most patients are treated with L-dopa/DCI,
often in combination with other antiparkinsonian agents
[8-13]. Unlike PD patients in Western countries, many
Chinese patients take medications at lower dosages and
have a lower prevalence of medication-related motor
complications.
China is a big country and economic development var-
ies greatly across the country. Our patients were re-
cruited from 42 university-affiliated teaching hospitalsrandomly selected from all teaching hospitals in seven
capital cities in four areas with various levels of economic
development. We identified some regional differences in
population and clinical characteristics of PD patients that
correlated with economic development. Compared to the
Mid-West, the least economically developed region, pa-
tients in the well-developed Gulf of Bohai were less likely
to have HYS ≥ 3 and had lower UPDRS-II scores, despite
a much longer mean disease duration. Patients in the
Gulf of Bohai were also more likely to be treated with
amantadine and selegiline in addition to L-dopa/DCI.
Studies in Western countries have reported that ap-
proximately 50-90% of PD patients develop motor com-
plications after 5-10 years of dopaminergic replacement
therapy [2-4,14-20]. We, however, observed a much lower
prevalence of motor complications among Chinese PD
patients, overall 8.6% for dyskinesias and 18.6% for motor
fluctuations. The difference in dyskinesias remained even
when comparing patients with similar disease duration
(median 4-6 years): 6.2% in Chinese patients compared to
27.8% (10.3-40%) identified by Ahlskog and Muenter in
their review article [2] or (median 14 years) 18.1% of
dyskinesias in Chinese patients compared to 58% in UK
patients [20]. The difference in motor fluctuations was
Table 3 Multivariate regression analyses of motor complications correlates among 737 L-dopa/DCI users
Variable Dyskinesias P Value Motor fluctuations P Value
Yes / no OR (95% CI) Yes / no OR (95% CI)
Age at onset (yr) ≥59 30 / 420 Reference 0.15 68 / 382 Reference 0.13
<45 11 / 49 2.32 (1.00 – 5.41) 14 / 46 1.20 (0.57 – 2.53)
45-58 22 / 205 1.31 (0.70 – 2.46) 55 / 172 1.63 (1·02 – 2·61)
PD duration (yr) <5 15 / 399 Reference 0.36 30 / 384 Reference 0.02
5-9 28 / 188 1.88 (0.79 – 4.51) 64 / 152 2.52 (1.31 – 4.85)
≥10 20 / 87 1.82 (0.59 – 5.59) 43 / 64 2.46 (1.05 – 5.76)
Hoehn -Yahr stage <3 38 / 540 Reference 0.03 76 / 502 reference <0.001
≥3 35 / 134 2.03 (1.08 – 3.82) 61 / 98 2.58 (1.62 – 4.11)
LD dose, mg/d <400 16 / 370 Reference 0.02 39 / 347 Reference 0.002
400-599 21 / 149 2.48 (1.20 – 5.13) 37 / 133 1.69 (0.99 – 2.91)
≥600 26 / 155 2.44 (1.20 – 4.98) 61 / 120 2.48 (1.49 – 4.14)
LD/DCI duration (yr) <2 14 / 294 Reference 0.44 23 / 285 Reference 0.07
2-4 15 / 215 1.04 (0.47 – 2.34) 36 / 194 1.58 (0.86 – 2.87)
≥5 34 / 165 1.73 (0.66 – 4.51) 78 / 121 2.42 (1.14 – 5.12)
Months to initiate ≤12 27 / 339 Reference 0.87 66 / 300 Reference 0.66
LD/DCI use >12 36 / 439 0.95 (0.49 – 1.83) 71 / 300 0.89 (0.54 – 1.48)
Initial treatment non LD/DCI 22 / 119 Reference 0.04 35 / 106 Reference 0.42
LD/DCI only 22 / 259 0.46 (0.22 – 0.95) 53 / 228 0.76 (0.42 – 1.36)
LD/DCI + others 19 / 296 0.41 (0.19 – 0.87) 49 / 266 0.67 (0.37 – 1.22)
Abbreviations: LD, L-dopa; DCI, decarboxylase Inhibitor; OR, odds ratios; CI, confidence interval.
Model adjusted for gender, age at onset, PD duration, Hoehn -Yahr stage, levodoap dose, LD/DCI duration, region, months to initiate LD/DCI use, and
initial treatment.
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similar difference was found when we stratified by age at
onset: for example, only 12.6% of our early-onset cases
(<50 years) had dyskinesias compared to 40% in USA
[21]. It is well established that these motor complications
are the result of L-dopa treatment [3,4]. A notable differ-
ence between Chinese patients and those in the West is
that Chinese patients took L-dopa (as well as other medi-
cations) at low dosages across all regions. Dosages also
remained low through the course of the disease. Further,
in our study, the presence of dyskinesias was related to
the dose of L-dopa, a finding consistent with that of other
studies [3,4]. Therefore, it is reasonable to suspect that
this low prevalence of motor complications may be in
part due to low-dose L-dopa/DCI treatment (median
400 mg/d).
In addition to L-dopa/DCI, 67.6% of Chinese patients
also used other antiparkinsonian agents as adjunctive
therapy at the time of our survey, also at low doses. As
disease duration increased, patients used more classes of
these agents, but still at low doses. Dopamine agonists
and amantadine were the most commonly used adjunct-
ive medications. Previous studies showed that amanta-
dine might delay the need for L-dopa/DCI in early PD
and provide an antidyskinetic effect in advanced patients[21-24]. In our study, 22.9% of Chinese PD patients
currently used, and 41.5% had ever used, amantadine
combined with L-dopa, a proportion much higher than
in Western patients (e.g., current users in the UK 5%, in
Italy 11.4%, and in Spain 18.8%) [15,16,25]. Adjunctive
selegiline can reduce the need for high-dose L-dopa/DCI
and may thus decrease the risk for motor fluctuations,
although at higher dosages (10 mg/d) it may induce
dyskinesias [4,26,27]. In Europe, the reported proportion
of adjunctive selegiline use ranges from 8.1 to 34.4%
[15,16,27]. In the present study, 10.2% of patients cur-
rently used, and 17.2% had ever used, selegiline, and typ-
ically at low doses (median 5 mg/d). Finally, a recent
meta-analysis confirmed that adjuvant therapy with
dopamine agonists reduced the need for higher L-dopa/
DCI dose, although it increased dyskinesias in patients
with later-stage PD [7]. Dopamine agonists were the most
commonly used adjunctive drug among Chinese patients,
but again at low doses consistently throughout disease
duration. For example, the median dose of piribedil
remained at 50-100 mg/day, that of amantadine at
200 mg/day, and that of selegiline at 5 mg/day.
The choice of multiple but low-dose medication may
reflect Chinese philosophy regarding the treatment of
chronic disease: “a small stream runs far”. Chinese
Zhang et al. BMC Research Notes 2014, 7:65 Page 7 of 8
http://www.biomedcentral.com/1756-0500/7/65treatment guideline of PD recommended “never go for full
effective dose” [28,29]. Many Chinese patients start L-
dopa/DCI in the low therapeutic range. The higher dose
that is standard in Western countries may achieve satis-
factory motor control sooner, but this may be at the ex-
pense of motor complications.
Deferral of L-dopa/DCI treatment has been recom-
mended in order to delay the onset of motor complica-
tions in patients younger than 70 years [22]. However, in
the current study, motor complications were less frequent
in patients who started with L-dopa/DCI alone or in com-
bination with other drugs than in those who started with
other drugs. L-dopa/DCI deferral was not associated with
a lower occurrence of dyskinesias or motor fluctuations.
Similar clinical observations have been made in other
studies [3,4,20,30]. Therefore, early initiation of low-dose
L-dopa/DCI may help to reduce the future occurrence of
motor complications. In support of this view, the lifetime
cumulative dose of L-dopa use was not related to PD
pathology among patients with younger age at onset and
longer duration [31]. In summary, early introduction of
low-dose symptomatic therapy may preserve basal ganglia
compensatory mechanisms [4,31].
A community-based study has recommended using
the emergence of axial symptoms (HYS 3) as a surrogate
of rapid progression [14]. Compared to studies in the
West with similar disease duration, HYS ≥3 disease was
not more common in our patients. For example, in pa-
tients with a median 14 years disease duration, the aver-
age HYS was 3.0 in our study compared with 3.1-3.4 in
other studies [20]. in those with about 9 years of disease
duration, the average HYS was 2.6 in our population
compared to 2.8 in others [11,12]. Median off times in
our Chinese patients with motor fluctuations were at a
moderate level. Moreover, compared with patients from
other regions, those from Bohai had a higher prevalence
of antiparkinsonism drug combinations (with a similar
low dosage for each form), resulting in higher LED.
Patients in Bohai had longer disease duration, especially
for more severe subjects (HYS ≥2.5), but their activities
of daily living were not worse and their quality of life
was possibly better, moreover cognitive impairment and
depressive symptoms were less frequent than in patients
from other areas. Therefore, the low prevalence of motor
complications among Chinese patients was not at the
expense of poor quality of life, rapid motor deterioration,
or prolonged off-times. The Chinese treatment strategy
adequately controlled motor signs and helped maintain
quality of life.
A multitude of neurotransmitters and receptors, includ-
ing glutamatergic, opioid, serotonergic, g-aminobutyric
acid (GABA)-ergic, adenosine, cannabinoid, adrenergic,
histaminergic, and cholinergic systems, have been re-
ported to play a role in the etiology of dyskinesias [32].The traditional approaches, which usually focus on a
single target, may not be appropriate, although non-
physiologic, pulsatile dopamine release seem to play
critical roles. Our clinical observation showed that com-
bined antiparkinsonian drugs with different mecha-
nisms of action at a small but effective dose reduced the
risk of dyskinesias. It might be explained that the com-
bined treatment targets simultaneously more than one
neurotransmitter system, through transcription factors
and intracellular signaling to alter expression of dyskin-
esia [32].
Although this is the largest clinical survey of PD pa-
tients in China, our study has several limitations. It is a
cross-sectional analysis of patients with various disease
durations. Therefore we were unable to make a direct
causal inference that low-dose medication leads to fewer
motor complications. Although our study is a good re-
flection of patients from urban areas, we might have
missed some patients from rural areas or small cities.
However, as explained previously, patients in rural areas
of small cities often lack medical resources and have to
seek help in large cities for PD diagnosis and treatment.
Finally, in China there are no family doctors; family-
based home care is the traditional customary, but not
institutional care for the elderly. Long-term healthcare is
often provided by family members, while patients with
long-term PD may see a neurologist less often, with the
result that our study may have preferentially included less
patients with longer disease duration. However, 42.2% of
our patients were ≥70 years old and 41.0% had average
disease duration of 9.2 (5-27) years.
Conclusion
In summary, this large clinical survey provides important
data on PD clinical practice in China. The difference ob-
served in medication use and also in the prevalence of
motor complications between patients in China and pa-
tients in the West may reflect cultural differences in med-
ical treatment. The possibility that low dose L-dopa/DCI
use in conjunction with other low-dose antiparkinsonian
medications may lead to fewer motor complications should
be further investigated in future prospective studies.
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